DBV Technologies expands its scientific advisory board
This article was originally published in Scrip
Executive Summary
DBV Technologies (France), a biopharmaceutical company focused on the development of non-invasive epicutaneous diagnostics and immunotherapies for allergies, has expanded its scientific advisory board with the appointments of Professor Gideon Lack and Associate Professor Philippe Eigenmann. Professor Lack is head of the children’s allergy service at Guy's and St Thomas' NHS Foundation Trust and a professor of paediatric allergy at King's College, London, while Professor Eigenmann is an associate professor at the department of infants and adolescents at the Hospital cantonal Universitaire Genève, Switzerland, specialising in paediatric allergy diagnosis and treatment.
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.